Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...

What if the huge design space for data-driven software could be efficiently mapped and explored in order to have tailor-made, optimized solutions? Researchers from Harvard combine analytical models, ...